瑞舒伐他汀联合贝那普利治疗早期糖尿病肾病的疗效

目的 探讨瑞舒伐他汀钙联合盐酸贝那普利治疗早期糖尿病肾病（DN）的疗效.方法 将124例早期DN患者随机分为两组,均给予降糖、饮食控制等常规治疗,对照组在常规治疗基础上加用贝那普利片20 mg/d,试验组在常规治疗基础上加用贝那普利片20 mg/d和瑞舒伐他汀钙片10 mg/d.两组疗程均为3个月.比较治疗前后两组患者收缩压（SBP）、舒张压（DBP）、空腹血糖（FBG）、糖化血红蛋白（HbA1c）、总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、血肌酐（SCr）及尿清蛋白排泄率（UAER）等指标的变化.结果 治疗后,两组患者SBP、DBP、FBG、HbA1c、TC、TG、LDL-C和UAER均较治疗前显著降低（P＜0.05）;且与对照组比较,试验组TC、TG、LDL-C及UAER的下降幅度更加显著（P＜0.05）.结论 与单用贝那普利相比,瑞舒伐他汀钙联合贝那普利能更好地延缓早期糖尿病肾病的进展.

Curative effects of rosuvastatin combined with benazepril on early diabetic nephropathy

Objective To discuss the curative effects of rosuvastatin calcium combined with benazepril on diabetic nephropathy（DN）. Methods 124 patients with early DN were randomly divided into two groups that received conventional treatments such as reducing the blood sugar and alimentary control, etc. The control group took benazepril tablets （ 20 mg/d） based on the conventional treatment. The experimental group took benazepril tablets（20 mg/d）and rosuvastatin calcium tablets（ 10 mg/d）based on the conventional treatment. The course of treatment was 3 months. Comparison was made in SBP, DBP, FBG, HbA1 c, TC, TG, LDL-C, HDL-C,SCr,and UAER between the two groups before and after treatment. Results After the treatment,the SBP,DBP,FBG,HbAlc, TC, TG, LDL-C, and UAER of both groups significantly decreased （ P 〈 0.05 ）. Compared with the TC, TG, LDL-C, and UAER of the control group, those of the experimental group decreased more significantly （ P 〈 0.05 ）. Conclusion Rosuvastatin calcium combined with benazepril delays the progress of early diabetic nephropathy more effectively than simple used of benazepril.